# Vaccine Therapy in Treating Patients With Metastatic Cancer

> **NCT00020267** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Lung Cancer
- Adult Soft Tissue Sarcoma
- Colorectal Cancer
- Bone Cancer
- Ovarian Sarcoma
- Melanoma
- Colon Cancer
- Rectal Cancer
- Breast Cancer
- Eye Cancer
- Uterine Sarcoma

## Interventions

- **DRUG:** interleukin-2
- **DRUG:** MAGE-12 peptide vaccine
- **DRUG:** Montanide ISA-51

## Key facts

- **NCT ID:** NCT00020267
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020267, "Vaccine Therapy in Treating Patients With Metastatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00020267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*